# A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male Subjects

> **NCT04670796** · PHASE1 · COMPLETED · sponsor: **Shanghai Henlius Biotech** · enrollment: 111 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HLX02
- **DRUG:** EU-sourced Trastuzumab (Herceptin®)
- **DRUG:** US-licensed Trastuzumab (Herceptin®)

## Key facts

- **NCT ID:** NCT04670796
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-02
- **Primary completion:** 2021-06-04
- **Final completion:** 2021-06-04
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2022-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04670796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04670796, "A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04670796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*